TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB^® Venture Market (the "OTCQB") under the symbol NRXBF. The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors.

As the sole public company developing therapies for spinal cord injury treatment with exosomes, NurExone is proud to broaden its financial market access. The OTCQB, a renowned U.S. trading platform, is a pivotal gateway to US trading, fostering an environment conducive to informed investment decisions. This enhances opportunities to attract investment and optimize shareholder value.

The Company is delighted to announce that it has also received Depository Trust Company ("DTC") eligibility for its shares on the OTCQB. DTC eligibility expands the Company's stock reach to a wider audience of potential investors and brokerage firms that mandate additional compliance measures. This move aims to enhance accessibility and potentially boost liquidity through online transactions.

Mr. Yoram Drucker, chairman of NurExone’s board, expressed his enthusiasm, stating, “Securing a place on the OTCQB and obtaining DTC eligibility exemplify our dedication to enriching shareholder engagement and liquidity. These achievements enable US investors to easily access and invest in NurExone. As pioneers in exosome-loaded nanodrug development for a variety of clinical conditions, notably spinal cord injuries, we're excited to provide the investing community with expanded avenues to join our innovation.”

Dr. Lior Shaltiel, CEO of NurExone added “Expanding our investor base will accelerate our efforts in developing solutions and therapies for the hundreds of thousands of patients worldwide suffering from traumatic spinal cord injuries.”

NurExone Biologic's common shares will continue trading on the TSX Venture Exchange (the “TSXV”) and on several stock exchanges in Germany including Frankfurt, Munich, or Tradegate. If, and when, the Company's common shares start to trade on the OTCQB, the Company's common shares will continue to trade on the TSXV under the symbol ‘NRX’ and in Germany under the symbol ‘J90’.

About NurExone Biologic Inc.

NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: [email protected]

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: [email protected]

Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: [email protected]

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including statements about the Company's future plans and intellectual property, the scientific and development and commercial activities to be carried out by the company, the efficient loading of exosomes, future potential manufacturing, clinical, licensing and marketing activities the treatment of certain conditions, trading the Company’s common shares on the OTCQB, and DTC eligibility. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Certain assumptions include the ability of the Company to commercialize its intellectual property internally and through licensing and that the Company has the appropriate team in order to realize commercialization. Risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property and dependence on the Company's strategic partners. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.